Pfizer jettisons IVD line
This article was originally published in The Gray Sheet
Executive Summary
European private equity firm Triton and PPM Ventures, an arm of Prudential, acquire in vitro allergy and autoimmune diagnostic testing business from Pfizer for $575 mil. Divestiture of the Sweden-based business had been projected since July, one year after the drug giant bought Pharmacia (1"The Gray Sheet" July 7, 2003, p. 8)...
You may also be interested in...
Pharmacia Device/Diagnostics Unit Ripe For Picking, Pfizer Says
Pfizer's July 1 announcement that it will explore strategic options for divesting Pharmacia's device and diagnostics division confirms the company's intentions to shed non-core assets
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.